JAFRAL Partners in First Clinical Trial Combining Electrochemotherapy with IL-12 Gene Therapy

JAFRAL is proud to serve as the GMP manufacturing partner for a pioneering clinical trial investigating the combination of electrochemotherapy with Interleukin-12 (IL-12) gene therapy to enhance local and systemic responses in the treatment of skin tumors.

The project is partially funded by the European Union, through the European Regional Development Fund (ERDF), and supported by the Slovenian Ministry of Education, Science and Sport. It is conducted within the framework of the Operational Program for the Implementation of the European Cohesion Policy 2014–2020.

This collaboration underscores JAFRAL’s commitment to advancing innovative therapies and supporting groundbreaking clinical research.

‍